What Happened?
Newton, MA-based Karyopharm Appointed Paula Larson as Associate Director, Compensation
Date of management change: November 25, 2021
Newton, MA-based Karyopharm Appointed Paula Larson as Associate Director, Compensation
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Paula Larson is Associate Director, Compensation at Karyopharm. Previously, Paula held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Diouf Anne-Marie, Andersen Nellie, Berube Nancy, Wettstein Bill, Joa Aileen, Borgstadt Daniel, Oza Ashish, Gutierrez Courtney, Dafney Namara, Watson Pat, Anderson Paula
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.